As reported on Yahoo! News, Bristol Myers Squibb (BMS) has received an expanded approval from the US Food and Drug Administration (FDA) for Camzyos (mavacamten), extending its use to pediatric patients aged 12 years and older who weigh at least 30 kg and are living with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). The therapy remains approved for adult patients and is indicated to improve symptoms and physical functioning in individuals affected by the condition.
The latest regulatory decision broadens access to a treatment option for younger patients with oHCM, a chronic cardiovascular disease that can significantly affect daily activities, exercise tolerance, and overall quality of life.
Phase III Data Supported Label Expansion
The FDA’s decision was based on results from the Phase III SCOUT-HCM trial, a randomized, double-blind, placebo-controlled study evaluating mavacamten in 44 adolescents between the ages of 12 and 17 years.
Clinical findings demonstrated that Camzyos met the study’s primary endpoint, delivering a statistically significant reduction in Valsalva left ventricular outflow tract (LVOT) gradient at 28 weeks compared with placebo. Reduction of LVOT obstruction is considered an important marker of disease improvement in patients with oHCM.
Investigators also reported a favorable safety profile during the trial. No participants receiving mavacamten experienced a decline in left ventricular ejection fraction (LVEF) below 50%, and no patients discontinued treatment because of adverse events. Serious adverse events occurred at similar rates in both treatment groups, affecting approximately 9% of patients receiving Camzyos and 10% of those receiving placebo. Researchers noted that no new safety signals emerged beyond those already recognized from adult studies.
Addressing an Unmet Need in Younger Patients
According to BMS, the approval represents an important advancement for adolescents and families managing symptomatic oHCM, a condition for which treatment options have historically been limited. The company highlighted the impact the disease can have during adolescence, a period marked by significant physical, social, and developmental milestones.
The expanded indication also adds to the growing evidence base supporting mavacamten, which has become one of the most extensively studied cardiac myosin inhibitors and has generated long-term follow-up data in adult populations.
Growing Global Presence
Camzyos first entered the US market in 2022 after receiving FDA approval for adults with symptomatic New York Heart Association (NYHA) Class II-III obstructive hypertrophic cardiomyopathy. Since launch, more than 25,000 patients in the United States have been treated with the therapy, with prescriptions written by over 5,000 healthcare professionals.
Beyond the US, the drug has secured approvals in more than 60 countries. Its global development program includes several late-stage clinical studies, such as EXPLORER-CN, HORIZON-HCM, and SCOUT-HCM, which have evaluated the therapy across diverse patient populations and geographic regions.
BMS stated that discussions with regulatory agencies outside the United States are ongoing as the company seeks to expand pediatric access to the treatment internationally.
Outlook
The FDA’s decision marks a significant milestone for the management of pediatric obstructive hypertrophic cardiomyopathy, bringing a targeted cardiac myosin inhibitor to a younger patient population for the first time. With positive efficacy and safety findings from SCOUT-HCM, the label expansion further strengthens mavacamten’s position as a key therapeutic option in the evolving treatment landscape for oHCM.
